SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 7, 2002
INTERLEUKIN GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-23413 94-3123681
----------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
135 Beaver Street, Waltham, MA 02452
----------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (781) 398-0700
------------------------------------------------------------------
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) EXHIBITS
99 Certification pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.
ITEM 9. REGULATION FD DISCLOSURE.
The information in this Current Report is being furnished pursuant to Item 9 and
shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. The information in this Current Report shall not be incorporated
by reference into any registration statement pursuant to the Securities Act of
1933, as amended. The furnishing of the information in this Current Report is
not intended to, and does not, constitute a representation that such furnishing
is required by Regulation FD or that the information this Current Report
contains is material investor information that is not otherwise publicly
available.
On November 7, 2002, the Company filed with the Commission its Quarterly Report
on Form 10-Q for the period ended September 30, 2002 accompanied by the
certification of Philip R. Reilly, Chief Executive Officer, and Fenel M. Eloi,
Chief Financial Officer, required pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERLEUKIN GENETICS, INC.
--------------------------
(Registrant)
Date: November 7, 2002 /s/ Fenel . M. Eloi
----------------------- ---------------------------------------
Fenel M. Eloi, Chief Operating Officer,
Chief Financial Officer, Treasurer and
Secretary and Treasurer
INDEX TO EXHIBITS
EXHIBIT NUMBER DESCRIPTION
-------------- -----------
99 Certification pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.